60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
WASHINGTON, May 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it will fund Babesia spp testing in chronic fatigue patient samples in a study to be conducted by North Carolina State College of Veterinary Medicine.
- WASHINGTON, May 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it will fund Babesia spp testing in chronic fatigue patient samples in a study to be conducted by North Carolina State College of Veterinary Medicine.
- Using PCR testing, the study will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue symptoms who present with neurologic conditions.
- Babesia spp is the parasite known to cause babesiosis, a potentially life-threatening disease in immunosuppressed patients.
- “We are pleased to provide support for this important study of babesiosis in patients with chronic fatigue syndrome symptoms,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow.